The Medical Letter on Drugs and Therapeutics
Fentanyl Sublingual Spray (Subsys) for Breakthrough Cancer Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a sublingual spray formulation of fentanyl (Subsys – Insys) for management of breakthrough pain in adult cancer patients who are receiving and are tolerant to opioid therapy (taking ≥60 mg/day of oral morphine or the equivalent). Fentanyl is already available in the US for intravenous, intrathecal, epidural, transdermal and transmucosal use.1,2

PHARMACOKINETICS — An unpublished study (summarized in the package insert) compared a single 400-mcg dose of fentanyl sublingual spray with the same dose of oral transmucosal fentanyl citrate (OTFC) in healthy adults. Median time to peak serum concentration (Tmax) was 1.5 hours with Subsys and 2.0 hours with OTFC; the peak serum concentration (Cmax) and area under the time-concentration curve (AUC) of the spray were 34% and 38% higher, respectively, than those of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fentanyl Sublingual Spray (Subsys) for Breakthrough Cancer Pain
Article code: 1390c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian